Chemomab Therapeutics Ltd. (CMMB)

NASDAQ: CMMB · IEX Real-Time Price · USD
3.94
-0.06 (-1.50%)
At close: Aug 15, 2022 4:00 PM
3.86
-0.08 (-2.03%)
After-hours: Aug 15, 2022 5:06 PM EDT
-1.50%
Market Cap 44.93M
Revenue (ttm) n/a
Net Income (ttm) -19.30M
Shares Out 11.40M
EPS (ttm) -1.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 91,795
Open 3.84
Previous Close 4.00
Day's Range 3.58 - 4.14
52-Week Range 2.53 - 17.39
Beta n/a
Analysts Buy
Price Target 22.44 (+469.5%)
Earnings Date Aug 12, 2022

About CMMB

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporat... [Read more...]

Industry Biotechnology
Founded 2004
Employees 20
Stock Exchange NASDAQ
Ticker Symbol CMMB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for CMMB stock is "Buy." The 12-month stock price forecast is 22.44, which is an increase of 469.54% from the latest price.

Price Target
$22.44
(469.54% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Chemomab Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update

─Chemomab to Host Webcast and Conference Call for Investors Today, August 12 at 8:00 am ET ─ TEL AVIV, Israel , Aug. 12, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage...

Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities

─Appoints Ilan Vaknin, PhD, as Vice President of Research & Development and Christina Crater, MD, as Vice President  of Clinical Development─ TEL AVIV, Israel , Aug. 12, 2022 /PRNewswire/ -- Chemomab Th...

Chemomab Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update

TEL AVIV, Israel , Aug. 1, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative thera...

Chemomab Presents Data Further Supporting the Mechanism of Action and Potential Efficacy of CM-101 in Primary Scleros...

—Data Presented at 2022 EASL International Liver ConferenceTM and First International  Extracellular Matrix Pharmacology Congress — TEL AVIV, Israel , June 27, 2022 /PRNewswire/ -- Chemomab Therapeutics...

Chemomab Therapeutics Appoints Jill M. Quigley, JD, to Its Board of Directors

—Ms. Quigley's Broad Biotechnology Industry Experience Encompasses Leadership Positions in Executive Management, Operations and Legal Affairs— TEL AVIV, Israel , June 21, 2022 /PRNewswire/ -- Chemomab T...

Chemomab Therapeutics to Present at June Investor and Scientific Conferences

TEL AVIV, Israel , June 9, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative thera...

Data Supporting Role of Chemomab's Novel Therapeutic Target CCL24 in Systemic Sclerosis Presented at EULAR 2022

—Poster Presentation of Reverse Translational Study Data Using Patient Samples Supports Role of CCL24 as a Therapeutic Target for Systemic Sclerosis— —Chemomab's CCL24-Neutralizing Antibody CM-101 Is Ex...

Chemomab Therapeutics to Participate in H.C. Wainwright Global Investment Conference

TEL AVIV, Israel , May 18, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative thera...

Chemomab Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update

-- Company to Host Conference Call for Investors Today, May 12 at 8:00 am ET --  TEL AVIV, Israel , May 12, 2022  /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotechnolo...

Chemomab Therapeutics to Report First Quarter 2022 Financial Results and Provide a Business Update

TEL AVIV, Israel , May 4, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therap...

Chemomab Therapeutics to Participate in Cantor Fitzgerald Rare Orphan Disease Summit

TEL AVIV, Israel , March 23, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative the...

New Strong Sell Stocks for March 14th

AVYA, BGS, and CMMB have been added to the Zacks Rank #5 (Strong Sell) List on March 14, 2022.

Other symbols: AVYABGS

Chemomab Reports on Two Scientific Presentations that Support the Potential Therapeutic Utility of CM-101 in Systemic...

—Translational Study Data Presented at 7th Systemic Sclerosis World Congress Confirms CCL24 is Elevated in Diffuse Cutaneous Systemic Sclerosis Patients; High CCL24 Serum Levels in Patients were Correla...

Chemomab Therapeutics Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update

TEL AVIV, Israel, March 9, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for...

Chemomab Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Business Update

TEL AVIV, Israel, March 2, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative thera...

Chemomab Therapeutics to Present at Aegis Virtual Conference

TEL AVIV, Israel, Feb. 10, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative thera...

Chemomab Therapeutics Names Jack Lawler Vice President of Global Clinical Development Operations

TEL AVIV, Israel, Jan. 4, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therap...

Chemomab to Participate in LifeSci Partners Annual Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthc...

TEL AVIV, Israel, Dec. 20, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative thera...

Chemomab Therapeutics Announces Expected Appointment of Dale R. Pfost as Chairman of the Board

TEL AVIV, Israel, Dec. 16, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab) a clinical-stage biotechnology company focused on the discovery and development of innovative therap...

Chemomab Therapeutics Names David M. Weiner, MD as Interim Chief Medical Officer

TEL AVIV, Israel, Dec. 3, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (NASDAQ: CMMB), (Chemomab) a clinical-stage biotech company focused on the discovery and development of innovative therapeutics ...

Chemomab Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Corporate Update

TEL AVIV, Israel, Nov. 12, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotech company focused on the discovery and development of innovative therapeutic...

Chemomab Announces Poster Presentation at AASLD's The Liver Meeting® 2021

TEL AVIV, Israel, Nov. 10, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotech company focused on the discovery and development of innovative therapeutic...

Chemomab to Present at Stifel 2021 Virtual Healthcare Conference

TEL AVIV, Israel, Nov. 9, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics...

Chemomab Therapeutics Names Donald R. Marvin Chief Financial Officer, Executive Vice President and Chief Operating Of...

TEL AVIV, Israel, Nov. 8, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab) a clinical-stage biotech company focused on the discovery and development of innovative therapeutics ...

Chemomab Therapeutics Hosting Key Opinion Leader Webinar on Systemic Sclerosis

TEL AVIV, Israel, Oct. 26, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) ("Chemomab"), a clinical-stage biotech company focused on the discovery and development of innovative therapeuti...